Gone are the days when kefir was a niche dairy beverage. Today, the cultured dairy drink has moved from the margins into the mainstream, thanks to rising interest in gut health, protein and functional nutrition.
The US kefir category is 29.1% in value and 26.1% in volume in the past year, a combination that points toward genuine consumption growth, according to analyst data supplied by Circana,
At the centre of the category’s expansion is Lifeway Foods. The company holds around 85% of the US kefir market, meaning that isn’t simply a leading brand, but a market-shaping force.
Lifeway’s presence in the category stretches beyond traditional kefir and into adjacent segments such as butter, spreads and even salad dressings. Flavoured and seasonal products, organic and grass-fed lines, probiotic smoothies with collagen, and protein and creatine drinks are all examples of how far the company has stretched its cultured dairy knowhow.
This differentiation strategy is crucial in a rapidly-expanding market segment that is increasingly competing not just with cultured yogurt but also with the broader functional drinks category including protein drinks and kombucha.
To remain competitive, Lifeway aims to address multiple consumer needs. Take Muscle Mates, for example. The lactose-free RTD range combines kefir cultures with 20g of protein and 5g of creatine and targets exercise, recovery and everyday wellness occasions.
The range reflects a wider shift across dairy toward products that promise more holistic nutrition.
The rise of GLP-1 weight management drugs could provide another platform for growth in the category, according to Circana’s dairy client insights leader, John Crawford.
Consumers using these medicines increasingly seek smaller, nutrient-dense options, with protein, lower sugar and digestive health key priorities.
Lifeway has identified the weight management cohort as potential consumers for probiotic, nutrient-dense foods. “The consumer focus on health and wellness continues to increase, gut health awareness is spreading and demand from GLP-1 users seeking nutrient-dense, probiotic foods is particularly strong,” Lifeway CEO Julie Smolyansky previously told investors.
Financially, Lifeway’s performance is in line with the market story. FY2025 net sales reached a record $212.5m, up from $186.8m, while net income increased to $13.9m from $9m. Momentum continued into the first quarter of 2026 when sales rose 36.7% year on year to $63m and net income reached $4.7m.
The company has also reiterated a target of $45m to $50m in adjusted EBITDA for FY2027.
Those figures, plus the state of the buoyant US kefir market, show why Lifeway’s leadership resisted repeated attempts from Danone to acquire the company.
The French multinational (which until recently owned a minority share in Lifeway) tabled offers of $283m and $307m to snap up the remaining shares in the kefir company, but Lifeway held firm arguing that the offers undervalued the business. Danone eventually sold its ~23% stake for around $67m in May 2026.
The exit removed an important distraction for the US kefir market share leader, as the financial and administrative burden of a prolonged boardroom standoff with its former business partner was beginning to weigh on performance.
Still, in mid 2026, no other player dominates the US kefir market like Lifeway does. But with demand for cultured dairy continuing to accelerate, the category is becoming increasingly attractive to competitors.
